Related Experiment Video
Updated: Jun 4, 2026
10:28
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
[Prevention of virus hepatitis A to E]
1Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, Hannover, Germany. cornberg.markus@mh-hannover.de
Der Internist
|February 23, 2011
Summary
Preventing viral hepatitis is crucial to avoid liver failure, cirrhosis, and cancer. Vaccines for Hepatitis A and B are effective, while Hepatitis C prevention relies on hygiene and early treatment, and Hepatitis E vaccines are in development.
Area of Science:
- Hepatology
- Virology
- Immunology
Context:
- Viral hepatitis infections pose significant global health risks, potentially leading to acute liver failure, chronic liver disease, cirrhosis, and hepatocellular carcinoma.
- Effective prevention strategies are essential to mitigate the burden of viral hepatitis and its severe long-term consequences.
Purpose:
- To provide a comprehensive overview of the current status and future prospects of viral hepatitis prevention, focusing on vaccination and prophylactic measures.
- To highlight the efficacy and challenges associated with vaccines for Hepatitis A (HAV), Hepatitis B (HBV), and Hepatitis E (HEV), and discuss non-vaccine strategies for Hepatitis C (HCV) and Hepatitis D (HDV).
Summary:
- Hepatitis A vaccination demonstrates high efficacy and long-lasting protection, significantly reducing HAV incidence. Hepatitis B vaccines are safe and effective, with ongoing research into improved formulations for special populations. Currently, no Hepatitis C vaccine is available, emphasizing the importance of hygiene and early treatment to prevent chronicity. Hepatitis D virus (HDV) infection is preventable by preventing Hepatitis B virus (HBV) infection. Hepatitis E virus (HEV) vaccines have shown promise in phase III trials, particularly relevant given emerging reports of chronic HEV infections in immunosuppressed individuals.
Impact:
- Successful vaccination programs for HAV and HBV have led to significant declines in infection rates, demonstrating the public health value of immunoprophylaxis.
- The development of new and improved vaccines, alongside robust hygiene measures and early therapeutic interventions, holds the potential to further reduce the global incidence and impact of viral hepatitis.
- Addressing the unmet need for a Hepatitis C vaccine and expanding access to existing vaccines are critical for global hepatitis elimination efforts.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:18Yellow Fever
Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flaviviridae family. It is transmitted primarily by Aedes and Haemagogus mosquitoes in tropical and subtropical regions of Africa and South America. After transmission through a mosquito bite, the virus initially replicates in skin-resident immune cells such as dendritic cells and macrophages. These cells then migrate to the lymph nodes, where viral replication increases, eventually leading to...
01:17Transmission-based Precautions I: Contact, Enteric, and Droplets
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...